Let’s start with the biggest two messages: Roche’s (RHHBY) $5 billion takeover of Spark Therapeutics (ONCE) (ONCE) means that large pharma companies are on a full-fledged buying spree, and that gene therapy, a long-awaited approach to treating hereditary diseases, has made the big time.

The Wall Street Journal reported Saturday that Roche (RHHBY) was in talks to buy Spark at a 150 percent premium to the smaller company’s market capitalization Friday. On Monday morning, the two companies announced that Roche would buy Spark for $4.8 billion, or $114.50 per share. Here are five things to keep in mind about this news for anyone who cares about the biotechnology sector.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy